IndustryCompany release

Evolus lifts Q3 revenue 13% to $78.0m and holds full-year guidance

🇺🇸 Evolus, Inc. (EOLS) · Wed 04 Nov 2026

The aesthetics company posted an adjusted EBITDA profit despite a GAAP operating loss, and expects FDA approval of Evolysse Sculpt by the end of the year.

Evolus reported third-quarter 2026 net revenue of $78.0 million on 4 November, driven by sales of its Jeuveau botulinum toxin and a growing contribution from its hyaluronic acid gel products. The headline in the company's release put the increase at 13%.

The company recorded a GAAP operating loss of $8.4 million for the quarter, but adjusted EBITDA was positive at $1.2 million.

Evolus reaffirmed its full-year revenue guidance of $330 million to $337 million. It also narrowed its guidance for non-GAAP operating expenses; the release headline describes the outlook as trimmed. The summary available does not give the revised range.

On the regulatory front, the company said it expects the US Food and Drug Administration to approve Evolysse Sculpt by the end of the year. It also noted new licensing and option arrangements: IBSA's Profhilo, Symatese's Estyme, and an injectable for hair growth. Financial and contractual terms for those deals were not available in the material reviewed.

What it means for your team

  • Evolysse Sculpt is the near-term regulatory event to watch, with an FDA decision expected by year-end according to the company.
  • The Profhilo, Estyme and hair-growth injectable arrangements point to a widening portfolio, which would bring more product-specific regulatory and post-market obligations if they proceed.
  • Market-access and commercial teams in aesthetics should note that hyaluronic acid gel sales are now a growing part of Evolus's revenue alongside its toxin.
  • Details of the licensing terms and the revised opex range were not in the available material, so those points should be checked against the full release.

Company's press release (SEC filing): Evolus, Inc. ↗

Article written by VigiEye from the official source (Evolus, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →